Skip to main content

Considering EnterraTM Therapy

Are you considering Enterra Therapy?

If you think Enterra Therapy may help relieve the chronic nausea and vomiting associated with gastroparesis, here’s some helpful information to consider. 

 Steps to receiving Enterra Therapy:

  1. Get evaluated 
    Your doctor will choose the appropriate screening tools and diagnostic tests for you. This often includes an initial physical exam, evaluation of medical history, and blood tests. Additionally, to confirm gastroparesis, your doctor may recommend an upper GI endoscopy and a Gastric Scintigraphy Test (Gastric Emptying Test). 
  2. Review the results
    Sit down with your doctor and carefully review the results from your screenings and evaluations. 
  3. Discuss treatment options 
    Ask your doctor to explain treatment options for your symptoms and/or diagnosis. Make sure to ask questions, review possible side effects, and share any concerns you may have. 
  4. Take action
    With your doctor’s help, choose the best treatment option for you, and follow your therapy plan—which may include diet modifications, follow-up visits, and other instructions. If you and your doctor decide that Enterra Therapy is right for you, your doctor will discuss the benefits and risks with you before the procedure. 

Enterra Therapy is indicated to relieve nausea and vomiting symptoms

While Enterra Therapy is intended to relieve the chronic nausea and vomiting associated with gastroparesis caused by diabetes or unknown causes, it is not a cure. 

Enterra Therapy has 5 randomized control trials completed and over 20 years of clinical research. You should speak with you doctor regarding the clinical data for Enterra Therapy.

Additionally, for patients who do experience relief with Enterra Therapy, results vary from person to person. Often, a combination of treatments is necessary to optimally control symptoms associated with gastroparesis. 

Enterra Therapy may not be right for everyone

Enterra Therapy is intended to reduce symptoms of chronic, drug-resistant nausea and vomiting associated with gastroparesis caused by diabetes or unknown causes in patients aged 18 to 70 years.

Additionally, here are some other important things to consider: 

  • Receiving an Enterra System Neurostimulator may limit your ability to undergo other medical procedures, including Magnetic Resonance Imaging (MRI) and diathermy. 
  • Some precautions are necessary around certain electrical and medical equipment and when going through theft detection and security screening gates 
  • Enterra Therapy is not appropriate for patients who aren’t candidates for surgical procedures, anesthesia, or both, because of either physical or mental conditions 
  • Enterra Therapy has not been evaluated in pregnant women or in patients younger than age 18 or older than age 70

Understand the risks associated with Enterra Therapy

When deciding whether Enterra Therapy is the right option for you, it’s important to understand that there are risks associated with the surgical implantation procedure, the Enterra System Neurostimulator and leads, and gastric electric stimulation therapy.

Complications from Enterra Therapy can include implant site pain, infection, stomach wall perforation, lead penetration, lead obstruction of intestines, lead/device problems, irritation/inflammation, uncomfortable/unwanted stimulation, and tissue damage, among others. For a complete list of adverse events, see Important Safety Information.

The information provided on this site is for general educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always talk to your doctor about the best treatment options for your individual situation.

NEXT: Receiving Enterra Therapy

MKT-D-00605, Rev A

IMPORTANT SAFETY INFORMATION

The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis. This system has not been evaluated for pregnant women, for use in patients under the age of 18, or patients over the age of 70. Patients should always discuss potential risks and benefits with their clinician.